大韩民国驻成都总领事馆与KOTRA成都代表处考察四川汇宇制药股份有限公司

2025年3月14日，大韩民国驻成都总领事馆和大韩贸易投资振兴公社（KOTRA）成都代表处的各位领导，在尹斗姬商务领事和边龙燮馆长的带领下，莅临四川汇宇制药股份有限公司三大基地考察指导，先后参观了成都汇宇研发基地、内江汇宇第二生产基地（原料药）、内江汇宇生产基地（制剂）。

On March 14, 2025, under the leadership of Yoon Du-hee, Commercial Consul of the Consulate General of the Republic of Korea in Chengdu, and Byun Yong-seop, Director of KOTRA Chengdu Office, a delegation visited Sichuan Huiyu Pharmaceutical’s three major sites, including the Chengdu Research Institute, Neijiang API Plant, and Neijiang Formulation Plant.

汇宇制药由执行副总裁韦治国及生产基地总经理任永春带领团队，对来访嘉宾进行了热情接待，并进行了深入的交流与探讨。

The delegation was warmly welcomed by Wei Zhiguo, Executive Vice President of Huiyu Pharmaceutical, and Ren Yongchun, General Manager of the Production Base, who led discussions on future collaboration and industry opportunities.

本次考察旨在实现两大目标：

This visit served two main purposes:

首先，此行代表了对中韩合作企业优秀代表的肯定与支持，进一步推动两国企业间的深度合作。

First, it demonstrated recognition and strong support for outstanding enterprises engaged in China-Korea cooperation, reinforcing the partnership between the two countries.

其次，本次考察也是筹备后续双边活动的重要一步。未来，计划以汇宇制药的CMO（合同生产组织）/CDMO（合同研发生产组织）业务为依托，搭建一个连接韩国创新药企业与中国头部医药企业的双向交流平台，促进中韩两国在医药领域的深度合作，推动医药贸易的发展。

Second, it was part of the preparation for upcoming bilateral activities. Huiyu Pharmaceutical aims to utilize its CMO (Contract Manufacturing Organization) and CDMO (Contract Development and Manufacturing Organization) business as a platform to facilitate exchanges between Korean innovative pharmaceutical companies and leading Chinese pharmaceutical enterprises, strengthening trade and collaboration in the pharmaceutical industry.

汇宇制药始终致力于全球医药健康事业的发展，未来将继续深化国际合作，助力全球制药产业链的协同创新。Huiyu Pharmaceutical remains committed to global healthcare advancement and will continue to enhance international partnerships, contributing to innovation and synergy across the pharmaceutical sector.